[关键词]
[摘要]
目的 评价喜炎平注射液治疗慢性阻塞性肺疾病急性加重期(AECOPD)的疗效与安全性。方法 检索PubMed、EMbase、The Cochrane Library、中国学术期刊全文数据库(CNKI)、中国生物医学文献数据库(CBM)、维普中文期刊全文数据库(VIP)和万方数据库中发表的关于喜炎平注射液治疗AECOPD的临床随机对照试验(RCT),从建库起至2020年2月20日,采用Jadad量表对纳入的文献进行质量评价,运用RevMan 5.3软件进行Meta-分析。结果 共纳入19项RCTs,包括1 500例患者。Meta-分析结果显示:喜炎平注射液组在总有效率[WMD=3.68,95%CI=(2.68,5.06),P<0.000 01]、呼吸困难的消失时间[WMD=-2.25,95%CI=(-2.53,-1.97),P<0.000 01]、白细胞计数[WMD=0.95,95%CI=(0.67,1.23),P<0.000 01]、中性粒细胞比值[WMD=3.16,95%CI=(-0.42,6.74),P=0.08]、二氧化碳分压[WMD=3.76,95%CI=(1.75,5.77),P=0.000 3]、氧分压[WMD=5.64,95%CI=(4.75,6.52),P<0.000 01]、FEV1占预计值百分比[WMD=3.46,95%CI=(0.47,6.46),P=0.02]、C反应蛋白[WMD=6.93,95%CI=(4.28,9.58),P<0.000 01]等指标的结果均优于对照组。结论 临床治疗AECOPD时加用喜炎平注射液可取得更好疗效,但本研究所纳入的文献质量偏低,需要更多规范的临床研究进一步印证。
[Key word]
[Abstract]
Objective To evaluate of curative effect of Xiyanping Injection in treatment of acute exacerbation of chronic obstructive pulmonary disease (AECOPD). Methods The randomized controlled trials (RCT) of Xiyanping Injection in the treatment of AECOPD from database establishment to February 20, 2020 were retrieved from PubMed, Embase, Cochrane library, CNKI, CBM, VIP and Wanfang database. Meta-analysis were performed with RevMan 5.3 software. Results A total of 19 RCTs were included, including 1 500 patients. Comparing to control group, Xiyanping Injection showed better therapeutic outcomes regarding to total effective rate[WMD=3.68, 95%CI=(2.68, 5.06), P<0.000 01], the disappearance time of dyspnea symptoms[WMD=-2.25, 95%CI=(-2.53, -1.97), P<0.000 01], white blood cell count[WMD=0.95, 95%CI=(0.67, 1.23), P<0.000 01], neutrophil ratio[WMD=3.16, 95%CI=(-0.42, 6.74), P=0.08], PaCO2[WMD=3.76, 95%CI=(1.75, 5.77), P=0.0003], PaO2[WMD=5.64, 95%CI=(4.75, 6.52), P<0.000 01], FEV1 accounts for The percentage of predicted value[WMD=3.46, 95%CI=(0.47, 6.46), P=0.02], C-reactive protein[WMD=6.93, 95%CI=(4.28, 9.58), P<0.000 01] than Control group. Conclusion In the treatment of AECOPD, Xiyanping Injection can achieve better curative effect, but the quality of the included study is poor, and more high-quality randomized controlled trials are needed to further confirm.
[中图分类号]
R974;R286.4
[基金项目]
国家中医药管理局国家中医临床研究基地业务建设科研专项课题(JDZX2015200);广东省中医院中医药科学技术研究专项(YN2015QN10)